Hormone Replacement Therapy News and Research

RSS

Hormone Replacement Therapy (HRT) sometimes called estrogent replacement therapy or ERT, refers to a woman taking supplements of hormones such as estrogen alone or estrogen with another hormone called progesterone (progestin in its synthetic form). HRT replaces hormones that a woman’s body should be making or used to make.

'Real world' guidelines may effectively prevent cardiovascular disease in women

Practical medical advice that works in the "real world" may more effectively prevent cardiovascular disease in women than recommendations based only on findings in clinical research settings, according to the 2011 update to the American Heart Association's cardiovascular disease prevention guidelines for women.

15 Feb 2011

New You Magazine about anti-aging management to re-launch in March

New You, the premier American consumer magazine about cosmetic surgery, will re-launch in March as the voice of the anti-aging industry in a strategic partnership with the American Academy of Anti-Aging Medicine.

9 Feb 2011

TS Wiley develops HRT protocol using Idiom Decision Manager tool

The Wiley Protocol is a trademarked, patent protected bio-identical hormone replacement therapy delivery system consisting of biomimetic estradiol and progesterone in a topical cream preparation – dosed to mimic the natural hormones produced by a woman's body when she was in her prime. The Wiley Protocol is the brainchild of TS Wiley, a popular author and frequent speaker at medical seminars around the world.

7 Feb 2011

Women's risk of getting breast cancer increases from one in nine to one in eight

The lifetime risk of getting breast cancer has risen from one woman in nine to one in eight - according to Cancer Research UK.

4 Feb 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

Modifiable and non-modifiable lifestyle factors influence breast cancer risk

Many risk factors for breast cancer are well studied and documented. Thus, scientists are sure by now that early first menstrual period, late onset of menopause and a family history of breast cancer are associated with an increased breast cancer risk.

19 Jan 2011

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

HRT with estrogen alone may reduce risk of breast cancer: Study

While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

10 Dec 2010

Can Pfizer rescue hormonal replacement therapy?

In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.

16 Nov 2010

New national campaign to drive awareness on DVT and PE prevention in women

As many as 600,000 people are affected by deep vein thrombosis (DVT) and pulmonary embolism (PE) every year, and more than half of those are never diagnosed. Some people experience swelling and varying levels of discomfort in the affected area, and some don't feel anything at all. But the symptoms of DVT can be similar to other conditions, like a pulled muscle, and because some people with DVT do not have any symptoms, there is often a delay in diagnosis. That's when DVT can be fatal.

28 Oct 2010

Endocrine disrupting chemicals may affect human reproductive system: Research

New research has provided the first evidence that 'gender bending' chemicals which find their way from human products into rivers and oceans can have a significant impact on the ability of fish to breed in UK Rivers.

27 Oct 2010

Hormone therapy increases breast cancer mortality risk, study finds

Hormone treatment after menopause, already known to increase the risk of breast cancer, also makes it more likely that the cancer will be advanced and deadly, a study finds.

21 Oct 2010

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.

21 Oct 2010

Link between low testosterone and heart disease deaths: Study

In a new study it was seen that men diagnosed with coronary heart disease with low testosterone were almost twice as likely to die over a seven year period. The team led by Prof Kevin Channer a cardiologist of the Royal Hallamshire Hospital in Sheffield looked at 930 men for the study. This study is in contrast to the popular belief that testosterone increases heart disease risk. The study was published in the journal Online First Heart.

21 Oct 2010

IMS launches new Recommendations to manage postmenopausal vaginal atrophy

To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.

7 Oct 2010

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

4 Oct 2010

HRT therapy can increase breast cancer risk

Breast cancer is one of the most common cancers, affecting up to one in eight women during their lives in Europe, the UK and USA. Large population studies such as the Women's Health Initiative and the Million Women Study have shown that synthetic sex hormones called progestins used in hormone replacement therapy, HRT, and in contraceptives can increase the risk of breast cancers.

30 Sep 2010

Study finds PEM scanners equivalent to breast MRI in detecting cancerous lesions

In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital (Boca Raton, FL) showed that Positron Emission Mammography (PEM) and breast MRI had comparably high ability to detect cancerous lesions.

29 Sep 2010

Breast cancer incidence drops, linked to decline in HRT use

A new Canadian study shows that a significant drop in breast cancer incidence among post-menopausal women from 2002 to 2004 coincided with a sharp drop in hormone replacement therapy (HRT) use during the same period. This is the first study to show the link between HRT use and breast cancer among Canadian women.

24 Sep 2010

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S. Second Circuit Court of Appeals [in New York] affirmed the legality of a settlement in which Bayer AG, in essence, paid Barr Pharmaceuticals Inc., a potential generic competitor, to drop its patent challenge to Cipro, a Bayer antibiotic."

9 Sep 2010